Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
作者信息
Verschoor Yara L, van de Haar Joris, van den Berg José G, van Sandick Johanna W, Kodach Liudmila L, van Dieren Jolanda M, Balduzzi Sara, Grootscholten Cecile, IJsselsteijn Marieke E, Veenhof Alexander A F A, Hartemink Koen J, Vollebergh Marieke A, Jurdi Adham, Sharma Shruti, Spickard Erik, Owers Emilia C, Bartels-Rutten Annemarieke, den Hartog Peggy, de Miranda Noel F C C, van Leerdam Monique E, Haanen John B A G, Schumacher Ton N, Voest Emile E, Chalabi Myriam
机构信息
Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Department of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
出版信息
Nat Med. 2024 May;30(5):1499. doi: 10.1038/s41591-024-02898-8.
Abstract
摘要
相似文献
1
Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.作者更正：阿替利珠单抗新辅助联合化疗治疗胃及胃食管交界腺癌：2期PANDA试验
Nat Med. 2024 May;30(5):1499. doi: 10.1038/s41591-024-02898-8.
2
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.胃和胃食管结合部腺癌的新辅助阿替利珠单抗联合化疗：Ⅱ期 PANDA 试验。
Nat Med. 2024 Feb;30(2):519-530. doi: 10.1038/s41591-023-02758-x. Epub 2024 Jan 8.
3
Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study.化疗联合阿替利珠单抗用于局部食管癌或食管胃交界腺癌切除术前及术后治疗：一项I/II期单臂研究
Cancers (Basel). 2024 Mar 31;16(7):1378. doi: 10.3390/cancers16071378.
4
Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial.局部晚期胃癌和食管胃结合部腺癌的新辅助治疗：一项前瞻性、多中心、单臂、II 期临床试验的研究方案。
BMC Gastroenterol. 2022 Jul 28;22(1):359. doi: 10.1186/s12876-022-02440-5.
5
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.胃/胃食管结合部可切除癌患者中 durvalumab 联合 FLOT 化疗的 III 期研究（Matterhorn 研究）
Future Oncol. 2022 Jun;18(20):2465-2473. doi: 10.2217/fon-2022-0093. Epub 2022 May 10.
6
RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.RACE 试验：新辅助放化疗对比化疗用于局部进展期可切除胃食管结合部腺癌患者——德国肿瘤学会、德国胃肠道肿瘤学会和德国放射肿瘤学会联合开展的一项 III 期随机研究
BMC Cancer. 2020 Sep 15;20(1):886. doi: 10.1186/s12885-020-07388-x.
7
Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.纳武利尤单抗联合化疗与单纯化疗作为中国晚期胃癌/胃食管交界癌/食管腺癌一线治疗的成本效益分析
Front Oncol. 2022 Apr 20;12:851522. doi: 10.3389/fonc.2022.851522. eCollection 2022.
8
A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma.局部晚期胃癌和胃食管结合部腺癌的全新辅助治疗的前瞻性 II 期临床试验。
Sci Rep. 2024 Mar 29;14(1):7522. doi: 10.1038/s41598-024-58177-6.
9
Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study.卡瑞利珠单抗联合奥沙利铂和替吉奥用于局部晚期胃或胃食管结合部癌新辅助治疗的有效性和安全性：一项Ⅱ期、单臂研究。
Cancer Med. 2024 Feb;13(3):e7006. doi: 10.1002/cam4.7006.
10
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.EORTC-1203-GITCG - “创新”试验：曲妥珠单抗单药与曲妥珠单抗加帕妥珠单抗联合化疗在 HER2 阳性胃和胃食管交界处腺癌围手术期治疗中的疗效对比：EORTC 胃肠道肿瘤研究组、韩国癌症研究组和荷兰上消化道肿瘤组的一项随机 II 期分组试验。
BMC Cancer. 2019 May 24;19(1):494. doi: 10.1186/s12885-019-5675-4.
引用本文的文献
1
Neoadjuvant chemotherapy combined with antiangiogenic therapy and immune checkpoint inhibitors for the treatment of locally advanced gastric cancer: a real - world retrospective cohort study.新辅助化疗联合抗血管生成治疗及免疫检查点抑制剂治疗局部晚期胃癌：一项真实世界回顾性队列研究
Front Immunol. 2025 Feb 4;16:1518217. doi: 10.3389/fimmu.2025.1518217. eCollection 2025.
2
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.新辅助纳武利尤单抗或纳武利尤单抗联合伊匹单抗治疗早期三阴性乳腺癌：一项 2 期适应性试验。
Nat Med. 2024 Nov;30(11):3223-3235. doi: 10.1038/s41591-024-03249-3. Epub 2024 Sep 16.
3
Current status of neoadjuvant immunotherapy for the treatment of gastric cancer.胃癌新辅助免疫治疗的现状。
Clin Transl Oncol. 2024 Sep;26(9):2097-2108. doi: 10.1007/s12094-024-03437-0. Epub 2024 Mar 20.
Zotero 插件